Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 46.66 -0.81 (-1.71%) Market Cap: 3.68 Bil Enterprise Value: 2.90 Bil PE Ratio: 0 PB Ratio: 4.19 GF Score: 33/100

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 11:00PM GMT
Release Date Price: $16.67 (-0.48%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Crinetics.

We're going to have a Q&A session in this room after the presentation. (Operator Instructions) So with that, let me turn it over to Crinetics' CEO, Scott Struthers for the presentation.

R. Scott Struthers
Crinetics Pharmaceuticals, Inc. - Founder, President, CEO & Director

Thank you, Jess. Thank you, everybody, for coming. It's really good to see people in 3D, although I miss seeing your kids and your dogs and some of the fun things we've had over the pandemic, but this is better.

So I'd like to tell you about Crinetics today. We're building a deep endocrine franchise and a company that can support it, time and again from product to product from discovery and soon into commercialization, being led by our Phase III program, which will read out this year, but there's a lot more behind that. So I'm going to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot